Anupam Rasayan India Ltd Q3 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Q3 FY26 earnings call: what management guided on revenue, margins and order book.

Published 8 Aug 2026 | Chemicals & Petrochemicals | Market Cap: ₹13.8K Cr

Q3 9MFY26 revenue grew 84% YoY to INR 1,730 crores, indicating strong growth momentum. Anupam Rasayan expects continued growth momentum into FY27, supported by a strong pipeline, deeper customer relationships, and expanding global footprints.

From Anupam Rasayan India Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.

📊 Revenue & Sales Performance

→Q3 9MFY26 revenue grew 84% YoY to INR 1,730 crores, indicating strong growth momentum.
→Management optimistic about continuing growth into FY27, driven by robust pipeline and deepening global customer relationships.
→Expansion supported by scaling up commercial molecules and ramping up capacity utilization.
→Focus on ramping up Pharma and Performance Material portfolios, which showed significant growth (Pharma up 85%, Performance Materials up 245% YoY for 9MFY26).
→Pipeline includes 65+ molecules in R&D/pilot stages, supporting future revenue growth.
→Acquisition of Jayhawk Fine Chemicals to strengthen North America footprint, expanding access to innovation-driven sectors (semiconductors, automotive, pharma, EV).
→Working capital management aims to reduce intensity from ~250 days to below 200 days by FY27, enhancing operational efficiency.
→Long-term value creation through expanding fluorination chemistry capabilities and supply chain resilience.

📈 Profitability & Margins

→Anupam Rasayan expects continued growth momentum into FY27, supported by a strong pipeline, deeper customer relationships, and expanding global footprints.
→The acquisition of Jayhawk Fine Chemicals is expected to be EPS accretive from day one, enhancing revenue and profitability through expanded US market presence and new customer validations.
→Management targets improvement in working capital days to below 200 by FY27, aiming around 180 days to improve cash flow and operational efficiency.
→Revenue growth drivers include ramp-up of commercial molecules, expanded fluorination chemistry capabilities, and increasing demand in Pharma, Performance Materials, and advanced materials sectors.
→EBITDA margins remain healthy, around 23-25%, with a focus on cost and process optimization, leveraging backward integration (e.g., Tanfac) and technology enhancements.
→Long-term value creation is driven by high entry barrier chemistries, complex syntheses, and sustained global customer stickiness, supporting disciplined earnings expansion.

See what Anupam Rasayan India Ltd said on profitability & margins — free account, 30 seconds.

🏗️ Capital Expenditure Plans

→The transcript does not explicitly mention any specific current or future capex or strategic capital investment plans.
→However, it highlights the strategic acquisition of Jayhawk Fine Chemicals, a US-based specialty chemicals company, expected to close soon, which represents a significant capital investment expanding Anupam's footprint in the US.
→This acquisition strengthens supply chain presence, technology, customer base, and product portfolio across high-value sectors like semiconductors, pharma, EV, and aerospace.
→The company also focuses on ramping up capacity utilization across manufacturing assets and smoothly integrating Jayhawk, implying ongoing investments in operational expansion.
→No detailed future capex figures or new plant/equipment investments were disclosed in the available transcript.
→The management emphasizes growth driven by expanding global footprints, pipeline commercialization, and technology enhancement, indicating possible capex aligned with these goals going forward.

💰 Fundraising & Capital Structure

The transcript from the earnings call of Anupam Rasayan India Limited does not mention any current or planned fundraising through debt or equity. Key points related to financing include: - No discussion or announcements about new debt or equity fundraising during the call. - Focus is on organic growth through acquisitions (e.g., Jayhawk Fine Chemicals) and operational scale-up. - The company aims for disciplined, long-term value creation without mentioning dilution or additional borrowings. - Working capital optimization is a priority to improve cash flow and financial efficiency. Thus, based on the available transcript, there are no indications of immediate or planned fundraising activities via debt or equity for FY27 or FY28 at this time.

See what Anupam Rasayan India Ltd said on fundraising & capital structure — free account, 30 seconds.

📋 Order Book & Pipeline

→In 9MFY26, Letters of Intent (LOIs) and contracts contributed over INR 250 crores of revenue, indicating strong conversion of the order pipeline into commercial revenue.
→The company has a robust pipeline with over 65 molecules across R&D and pilot stages in Pharma and Polymer segments.
→The Pharma segment has more than 30 molecules under development and pilot stages.
→The Polymer and Electronic Material vertical has 35+ molecules in development and pilot stages.
→The strong customer pipeline and order book visibility support optimistic growth momentum into the next fiscal year.

Key Metrics

How does Anupam Rasayan India Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Anupam Rasayan India Ltd

See full Chemicals & Petrochemicals sector rankings

Price

₹1,244

Market Cap

₹13.8K Cr

P/E Ratio

81.4

Anupam Rasayan India Ltd — Quarterly revenue & net profit

Revenue Net Profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹636 Cr, net profit ₹56 Cr.

Full financials →

What Anupam Rasayan's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

Clean Science (Q3 FY26)
Trade deal with Europe starting in FY '27 to potentially reduce tariffs (5.5%-12%), helping competitiveness against China. Key concall takeaways from Clean…
Aether Industri. (Q3 FY26)
The company currently services Baker Hughes with 8 products in commercial production (Site 4) generating a run rate of INR 60 crores this quarter. Key concall…
Kesar Petroprod. (Q3 FY26)
Export markets constitute about 40% of sales, served through 7-8 distributors across geographies. Key concall takeaways from Kesar Petroprod.'s Q3 FY26…
Tata Chemicals (Q3 FY26)
Indian salt capacity expansion of 210 KT per annum with INR 515 crore investment is underway to meet growing demand. Key concall takeaways from Tata…

Compare:vs Solar Industries vs Pidilite Inds.vs SRF

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Anupam Rasayan India Ltd Q3 FY26 results?

What is Anupam Rasayan India Ltd share price analysis?

Anupam Rasayan India Ltd currently shows a neutral. The stock trades at a P/E of 81.4 with a market cap of ₹13,847 Cr. Investors should review the full earnings analysis for detailed insights.

Is Anupam Rasayan India Ltd planning capital expenditure?

The transcript does not explicitly mention any specific current or future capex or strategic capital investment plans.

Keep Anupam Rasayan India Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.